Cost Effectiveness Analysis Within an RCT

Henry Glick
University of Pennsylvania
www.uphs.upenn.edu/dgimhsr
07/19/13

Outline
• (Very) Brief introduction to economic evaluation
• (Very) Brief description of ideal economic evaluation in a clinical trial
• 6 issues in designing economic evaluations in clinical trials
  – What Medical Service Use Should We Collect?
  – How Should We Value Medical Service Use?
  – What Effectiveness Measure Should We Use?
  – How Naturalistic Should Study Be?
  – What Sized Sample Should We Study?
  – How Should We Interpret Results From Multicenter (Multinational) Trials?

Brief Introduction to Economic Evaluation
• Types of Analysis
• Types of costs
• Perspective

Types of Analysis
• Types of analysis
  – Cost identification
  – Cost-effectiveness
  – Cost-benefit
  – Cost-utility
  – Net monetary benefit
  – Value of information
• Generally distinguished by:
  – Outcomes included: e.g., costs only vs costs and effects
  – How outcomes are quantified: e.g., as money alone or as health and money

Cost-Identification / Cost-Minimization
• Estimates difference in costs between interventions, but not difference in outcomes
• Appropriate when two therapies of equal efficacy are compared
• Introduction of sampling uncertainty undermine uses of cost-identification analysis
  – When effects don’t differ significantly – i.e., failure to reject null hypothesis – are we able to differentiate between:
  • One therapy costing less and doing same or more (cost-minimization) Vs
  • Alternative costing more and doing more (cost-effectiveness)

Cost-Effectiveness Analysis
• Estimates differences in costs and differences in outcomes between interventions, but costs and outcomes are measured in different units
• Costs usually measured in money terms; outcomes in some other units

\[
\frac{\text{Costs}_1 - \text{Costs}_2}{\text{Effects}_1 - \text{Effects}_2}
\]
• Results meaningful in comparison with:
  – Predetermined threshold / cut-off for willingness to pay (e.g., $50,000 per QALY)
  – Other accepted and rejected interventions (league tables)
Cost-Benefit Analysis
• Estimates differences in costs and differences in benefits in same (usually monetary) units
• As with cost-effectiveness, requires a set of alternatives

Other Types of Analyses
• Cost-utility analysis
  – Form of cost-effectiveness analysis where effectiveness expressed in terms of utility (e.g., quality-adjusted life years)
• Net monetary benefits
  – Part cost-effectiveness, part cost-benefit
  – Multiply difference in effectiveness by threshold WTP and subtract costs ($W \Delta Q - \Delta C$)
  • Results greater than zero indicate value of difference in effects greater than difference in costs

Review
• Investigators compared 2 treatments, “LessCost” and “MoreCure”
• They found that “LessCost” was less expensive and recommended its adoption by physicians
  – 1000 vs 1200
• What type of economic analysis are the investigators carrying out?
• Do you agree with their conclusion?

Example 2
• Investigators compared 2 treatments, “LessCost” and “MoreCure.” They observed:

<table>
<thead>
<tr>
<th></th>
<th>MoreCure</th>
<th>LessCost</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost</td>
<td>1200</td>
<td>1000</td>
<td>200</td>
</tr>
<tr>
<td>Benefit</td>
<td>3000</td>
<td>1500</td>
<td>1500</td>
</tr>
</tbody>
</table>
• Authors concluded that MoreCure is net beneficial.
• What type of economic analysis are the investigators carrying out?
• Do you agree with their conclusion?

Example 3
• Investigators compared 2 treatments, “LessCost” and “MoreCure.” Observed that MoreCure cost 200 more than LessCost and provided .03 additional QALYs
• Authors recommended that MoreCure was good value for the cost
• What type of economic analysis are the investigators carrying out?
• Do you agree with their conclusion?

Types of Costs
• Direct: medical or nonmedical
• Time costs: Lost due to illness or to treatment
• Intangible costs
• Types of costs included in an analysis depend on:
  – What is affected by illness and its treatment
  – What is of interest to decision makers
  • e.g., a number of countries’ decision makers have indicated they are not interested in time costs
Study Perspective

- Economic studies should adopt 1 or more “perspectives”
  - Societal
  - Payer (often insurer)
  - Provider
  - Patient
- Perspective helps identify services that should be included in analysis and how these services should be cost out
  - e.g., patient out-of-pocket expenses may be excluded from insurer perspective
  - Not all payments may represent costs from societal perspective

Good Value for the Cost

- Economic data collected as secondary (or primary) endpoints in randomized trials commonly used in evaluation of “value for the cost”
  - Short-term economic impacts directly observed
    - Within-trial analysis
  - Longer term impacts potentially projected by use of decision analysis
    - Long term projection
  - Reported results: point estimates and confidence intervals for estimates of:
    - Incremental costs and outcomes
    - Comparison of costs and effects

Sample Results Table

<table>
<thead>
<tr>
<th>Analysis</th>
<th>Point Estimate</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incremental Cost</td>
<td>-713</td>
<td>-2123 to 783</td>
</tr>
<tr>
<td>Incremental QALYs</td>
<td>0.13</td>
<td>0.07 to 0.18</td>
</tr>
<tr>
<td>Cost-Effectiveness Analysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Principal Survival Benefit</td>
<td>Dominates</td>
<td>Dom to 6650</td>
</tr>
<tr>
<td>-33%</td>
<td>Dominates</td>
<td>Dom to 9050</td>
</tr>
<tr>
<td>+33%</td>
<td>Dominates</td>
<td>Dom to 5800</td>
</tr>
<tr>
<td>Drug Cost</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-50%</td>
<td>Dominates</td>
<td>Dom to 4850</td>
</tr>
<tr>
<td>+50%</td>
<td>Dominates</td>
<td>Dom to 8750</td>
</tr>
<tr>
<td>Discount rate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0%</td>
<td>Dominates</td>
<td>Dom to 6350</td>
</tr>
<tr>
<td>7%</td>
<td>Dominates</td>
<td>Dom to 7000</td>
</tr>
</tbody>
</table>

Steps in Economic Evaluation

Step 1: Quantify costs of care
Step 2: Quantify outcomes
Step 3: Assess whether and by how much average costs and outcomes differ among treatment groups
Step 4: Compare magnitude of difference in costs and outcomes and evaluate “value for costs”
  - e.g. by reporting a cost-effectiveness ratio, net monetary benefit, or probability that ratio is acceptable
  - Potential hypothesis: Cost per quality-adjusted life year saved significantly less than $75,000
Step 5: Perform sensitivity analysis

Ideal Economic Evaluation Within a Trial

- Conducted in naturalistic settings
  - Compares therapy with other commonly used therapies
  - Studies therapy as it would be used in usual care
- Well powered for:
  - Average effects
  - Subgroup effects
- Designed with an adequate length of follow-up
  - Allows assessment of full impact of therapy
- Timely
  - Can inform important decisions in adoption and dissemination of therapy

Ideal Economic Evaluation Within a Trial (II)

- Measure all costs of all participants prior to randomization and for duration of follow-up
  - Costs after randomization—cost outcome
  - Costs prior to randomization—potential predictor
- Independent of reasons for costs
- Most feasible when:
  - Easy to identify when services are provided
  - Service/cost data already being collected
  - Ready access to data
Difficulties Achieving an Ideal Evaluation

• Settings often controlled
• Comparator isn’t always most commonly used therapy or currently most cost-effective
• Investigators haven’t always fully learned how to use new therapy under study
• Sample size required to answer economic questions may be greater than sample size required for clinical questions
• Ideal length of follow-up needed to answer economic questions may be longer than follow-up needed to answer clinical questions

Trade-off

• These trials may be only source of information needed for important early decisions about adoption and diffusion of therapy

TRADE-OFF: Ideal vs best feasible

Issue #1: What Medical Service Use Should We Collect?

• Real/perceived problem: Don’t have sufficient resources to track all medical service use

Limited Data Collection Resources

• Availability of administrative data may reduce costs of tracking all medical service use
• If administrative data are unavailable:
  – Measure services that make up a large portion of difference in treatment between patients randomized to different therapies under study
    • Provides an estimate of cost impact of therapy
  – Measure services that make up a large portion of total bill
    • Minimizing unmeasured services reduces likelihood that differences among them will lead to biased estimates
    • Provides a measure of overall variability

Measure as Much as Possible

• Best approach: measure as many services as possible
  – No a priori guidelines about how much data are enough
  – Little to no data on incremental value of specific items in economic case report form
• While accounting for expense of collecting particular data items

Document Likely Service Use During Trial Design

• Can improve decisions by documenting types of services used by patients who are similar to those who will be enrolled in trial
  – Review medical charts or administrative data sets
  – Survey patients and experts about kinds of care received
  – Have patients keep logs of their health care resource use
• Guard against possibility that new therapy will induce medical service use that differs from current medical service use
Limit Data to Disease-Related Services?

• Little if any evidence about accuracy, reliability, or validity of such judgments
• Easy for judgments to be flawed
• Investigators routinely attribute AEs to intervention, even when participants received vehicle/placebo

Medical practice often multifactorial: modifying disease in one body system may affect disease in another body system

– In Studies of Left Ventricular Dysfunction, hospitalizations "for heart failure" (and death) reduced by 30% (p<0.0001)
– Hospitalizations for noncardiovascular reasons reduced 14% (p = 0.006)

General Recommendations

• General Strategy: Identify a set of medical services for collection, and assess them any time they are used, independent of reason for use
• Decision to collect service use independent of reason for use does not preclude ADDITIONAL analyses testing whether designated "disease-related" costs differ

Issue #2. How Should We Value Medical Service Use?

• Availability of billing data may simplify valuation

If billing data aren’t available, common strategy is to measure service use in trial and identify price weights (unit costs) to value this use

Common Sources of Price Weights

• Hospital care
  – Hospital bills adjusted by Federal cost-to-charge ratios
  – DRG payments
  – National inpatient sample
    • Calculator or dataset
    – Other administrative databases that include patient-level clinical and cost information
• Physician services
  – Medicare fee schedule
  – Other administrative databases

Common Sources (2)

• Laboratory tests
  – Clinical Diagnostic Laboratory Fee Schedule
• Durable equipment
  – Medicare Durable Good Fee Schedule
• Pharmaceuticals
  – Federal Supply Schedule
  – Adjusted AWP
  – National Average Drug Acquisition Cost (NADAC)
  – National Average Retail Prices (NARP)

Concomitant Medications

• Common to be very precise when costing study medications
• Greater problems posed by costing out concomitant medications
  – Number of agents / routes of administration / dosages / # of doses
• In many studies, investigators simplify process:
  – Categorize drugs into classes
  – Identify 1 or 2 representatives of class (including route / dosage / # of doses)
  – Cost out representative drugs and use their cost as cost for all members of class
Issue #3. What Effectiveness Measure?

- Can calculate a ratio for any outcome
  - Cost per toe nail fungus day averted
- To be an informative cost-effectiveness ratio, must know what we are willing to pay for outcome
  - In many jurisdictions, quality-adjusted life year (QALY) is recommended outcome of cost-effectiveness analysis
- Some resistance to this outcome, particularly from Congress
  - [PCORI] "shall not develop or employ a dollars per quality adjusted life year (or similar measure that discounts the value of a life because of an individual’s disability) as a threshold to establish what type of health care is cost effective or recommended"

QALYs

- Economic outcome that combines preferences for both length of survival and its quality into a single measure
- Help us decide how much we should pay for:
  - A therapy that saves fully functional lives/life years
    vs
  - A therapy that saves less than fully functional lives/life years (e.g., a drug for heart failure that extends survival, but patients spend extra time in NYHA class III)
  vs
  - A therapy that doesn’t save lives/life years but improves patients’ functioning (e.g., patients with heart failure spend most of their remaining years in NYHA class I instead of NYHA class III)

QALY Scores

- QALY or preference scores generally range between 0 (death) and 1 (perfect health)
  - For example, a health state with a preference score of 0.8 indicates that a year in that state is worth 0.8 of a year with perfect health
  - There can be states worse than death with preference scores less than 0

Prescored Health State Classification Instruments

- Dominant approach for QALY measurement uses prescored health state classification instruments (indirect utility assessment)
- Participants’ report their functional status across a variety of domains
- Preference scores derived from scoring rules that have usually been developed by use of samples from general public

Prescored Instruments

- A number of prescored instruments are currently available for measurement of preference scores for current health
  - EuroQol instrument (EQ-5D), 3 and 5 level
  - Health Utilities Index Mark 2 (HUI2)
  - Health Utilities Index Mark 3 (HUI3)
  - SF-6D
- Most ask participants or their proxies to report on health status of patient, not preference

EQ-5D, HUI2, and HUI3

- EQ-5D, HUI2, and HUI3 are three of the most commonly used prescored preference assessment instruments
- All three of these instruments share features of ease of use
  - e.g., high completion rates and ability to be filled out in 5 min or less
- All have been used to assess preferences for a wide variety of diseases
Superiority?
• Widespread direct comparison of instruments doesn’t provide an answer about which instrument should be used in which circumstances
  – Evaluation of correlations between instruments’ preference scores find good correlation
  – Evaluation of correlations between instruments’ scores and convergent validity criteria find good correlation
  – Evaluation of instruments’ responsiveness find good responsiveness
• Most studies have concluded:
  – The instruments differ in their scores
  – Little evidence that one instrument superior to others

Issue # 4. How Naturalistic?
• Primary purpose of cost-effectiveness analysis:
  Inform real-world decision-makers about how to respond to real-world health care needs
• Greater naturalism, in terms of participants, analysis based on intention to treat, and limitation of loss to follow-up, implies greater likelihood that data developed within trial will speak directly to decision question

#4a. Intention to Treat
• Economic questions relate to treatment decisions (e.g., whether to prescribe a therapy), not whether patient received drug prescribed nor whether, once they started prescribed drug, they were switched to other drugs
  – Implication: costs and effects associated with these later decisions should be attributed to initial treatment decision
• Thus, trial-based cost-effectiveness analyses should adopt an intention-to-treat design

#4b. Loss to Follow-up
• Trials should be designed to minimize occurrence of missing data
  – Study designs should include plans to aggressively pursue participants and data throughout trial
  – Strategies may include:
    1) intensive outreach to reschedule assessment, followed by
    2) telephone assessment, followed by
    3) interview of a proxy who had been identified and consented at time of randomization

#4c. Protocol-Induced Costs and Effects
• Common concerns:
  – Standardization of care in clinical trial protocols often means that care delivered in trials differs from usual care
    • Protocol may require substantial number of investigations and diagnostic tests that would not be performed under normal clinical practice
  – Protocols often prescribe aggressive documentation and treatment of potential adverse effects that differ from usual care
• Omit these costs???
Omission of Protocol-Induced Costs?

- Criterion for including costs should NOT be “Would services have been provided in usual care”
- Should be: “Could services have affected care / outcomes (and thus costs and effects)”
- No problem omitting services that cannot affect care / services
  - e.g., Cost of genetic samples that will not be analyzed until after follow-up is completed
- More problematic to omit services that can change treatment and affect outcome
  - “Cadillac” costs may yield “Cadillac” outcomes
  - Would have to adjust both costs and their effects on outcomes

Biases?

- Protocol-induced testing may bias testing cost to null
  - There might be a difference in this testing in usual care, but it can’t be observed if everyone is routinely tested
- Protocol-induced testing may bias cost and outcome in an unknown direction
  - Trial’s extra testing may lead to:
    - Avoidance of outcomes that would have occurred had there been no extra detection and treatment
    - Early detection and treatment of outcomes when they are less severe and easier to treat
    - Detection and treatment of outcomes that wouldn’t have been detected and treated in usual care

Issue #5. What Sized Sample Should We Study?

- A goal of sample size and power calculation for cost-effectiveness analysis is to identify likelihood that an experiment will allow us to be confident that a therapy is good or bad value when we adopt a particular willingness to pay
  - e.g., We:
    - May expect a point estimate for cost-effectiveness ratio of 20,000 per QALY
    - May be willing to pay at most 75,000 per QALY
    - Want an experiment that provides an 80% chance (i.e., power) to be 95% confident (alpha) that therapy is good value

Sample Size Formula

- At most basic level, sample size for cost-effectiveness is calculated using same formula as used for sample size for a difference in any continuous variable:
  \[
  n = \frac{2 \left( z_\alpha + z_\beta \right)^2 \cdot s_{d_{nmb}}^2}{\Delta n_{mb}^2}
  \]
  where \( n \) = sample size/group; \( z_\alpha \) and \( z_\beta \) = z-statistics for \( \alpha \) (e.g., 1.96) and \( \beta \) (e.g., 0.84) errors; \( s_{d_{nmb}} \) = standard deviation for NMB; and \( \Delta n_{mb} \) = expected difference in NMB

Sample Size Formula (2)

- Complexities arise because 1) difference being assessed is difference in NMB (WΔQ – ΔC) and 2) standard deviation of NMB is a complicated formula
- Data needed to calculate sample size include:
  - Difference in cost
  - SD, difference in cost
  - Difference in effect
  - SD, difference in effect
  - \( Z_\alpha \) and \( Z_\beta \)
  - Correlation of difference in cost and effect
  - Willingness to pay

Full Formula

\[
\frac{2 \left( z_\alpha + z_\beta \right)^2 \left( s_{d_{nmb}}^2 + \left( W \cdot s_{d_{nmb}} \right)^2 - \left( 2 W \cdot p \cdot s_{d_{nmb}} \cdot s_{d_{nmb}} \right) \right)}{\left( W \cdot \Delta Q - \Delta C \right)^2}
\]
Correlation of Difference

- When increasing effects are associated with decreasing costs, a therapy is characterized by a negative (win/win) correlation between difference in cost and effect
  - e.g., asthma care
- When increasing effects are associated with increasing costs, a therapy is characterized by a positive (win/lose) correlation between difference in cost and effect
  - e.g., life-saving care
- All else equal, fewer patients need to be enrolled when therapies are characterized by a positive correlation than when therapies are characterized by negative correlation

Effect of $SD_q$ VS $SD_c$ on Sample Size

- Commonly thought that sample size for cost-effectiveness driven more by standard deviation for cost than it is by SD for effect
  - If not, why would we need a larger sample for economic outcome than we do for clinical outcome?
- However, if willingness to pay is substantially greater than standard deviation for cost, percentage changes in QALY SD can have a substantially greater effect on sample size than will equivalent percentage changes in cost SD

Economic Vs Clinical Sample Sizes

- Sample size required to answer economic questions often larger than sample size required to answer clinical questions
  - But it need not be
- $\Delta C$ and $\Delta Q$ are a joint outcome just as differences in nonfatal CVD events and all cause mortality are often combined into a joint outcome
- In same way that we can have more power for joint cardiovascular outcome than either individual outcome alone, we can have more power for cost-effectiveness than we do for costs or effects alone

Willingness to Pay and Identification of an Appropriate Outcome Measure

- Sample size calculations require stipulation of willingness to pay for a unit of outcome
- In many medical specialties, researchers use disease specific outcomes
- Can calculate a cost-effectiveness ratio for any outcome (e.g., cost/case detected; cost/abstinence day), but to be informative, outcome must be one for which we have recognized benchmarks of cost-effectiveness
  - Argues against use of too disease-specific an outcome for economic assessment

Issue #6. How Should We Interpret Results From Multicenter (Multinational) Trials?

- Problem:
  - There has been growing concern that pooled (i.e., average) economic results from multicenter (multinational) trials may not be reflective of results that would be observed in individual centers (countries) that participated in trial
  - Similar issues arise for any subgroup of interest in trial (e.g., more and less severely ill patients)

Common Sources of Concern

- Differences in morbidity/mortality patterns; practice patterns (i.e., medical service use); and absolute and relative prices for this service use (i.e., price weights)
- Decision makers may find it difficult to draw conclusions about value of therapies that were evaluated in multicenter (multinational) trials
Bad Solutions

- Use trial-wide clinical results, trial-wide medical service use, and price weights from one center (country)
  - e.g., to tailor results to U.S., just use U.S. price weights, and conduct analysis as if all participants were treated in U.S.
- Use trial-wide clinical results and use costs derived from subset of patients treated in country
- Ignore fact that clinical and economic outcomes may influence one another (cost affects practice which affects outcome; practice affects outcome which affects cost)

Impact of Price Weights vs Other Variation

<table>
<thead>
<tr>
<th>Country</th>
<th>Price weight</th>
<th>Country-Specific Costs</th>
<th>Country-Specific Costs and Effects†</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>46,818</td>
<td>5921</td>
<td>11,450</td>
</tr>
<tr>
<td>2</td>
<td>57,636</td>
<td>91,906</td>
<td>60,358</td>
</tr>
<tr>
<td>3</td>
<td>53,891</td>
<td>90,487</td>
<td>244,133</td>
</tr>
<tr>
<td>4</td>
<td>69,145</td>
<td>93,326</td>
<td>181,259</td>
</tr>
<tr>
<td>5</td>
<td>65,800</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Overall</td>
<td>45,892</td>
<td>45,892</td>
<td>45,892</td>
</tr>
</tbody>
</table>

Two Analytic Approaches To Transferability

- Two approaches -- which rely principally on data from trial to address these issues -- have made their way into literature
  - Hypothesis tests of homogeneity (Cook et al.)
  - Multi-level random-effects model shrinkage estimators


Hypothesis Tests Of Homogeneity

- Evaluate homogeneity of results from different countries
  - If no evidence of heterogeneity (i.e., a nonsignificant p-value for test of homogeneity), and test considered powerful enough to rule out economically meaningful differences in costs, can’t reject that pooled economic result from trial applies to all of countries that participated in trial
  - If evidence of heterogeneity, should not use pooled estimate to represent result for individual countries
    - Method less clear about result that should be used instead

Estimation

- Multi-level random-effects model shrinkage estimation assesses whether:
  - Observed differences between countries are likely to have arisen simply because we have divided trial-wide sample into subsets VS
  - Whether they are likely to have arisen due to systematic differences between countries
- Borrows information from mean estimate to add precision to country-specific estimates
- Methods have potential added advantage of providing better estimates of uncertainty surrounding pooled result than naive estimates of trial-wide result

Summary

- Clinical trials may provide best opportunity for developing information about a medical therapy’s value for cost early in its product life
- When appropriate types of data are collected and when data are analyzed appropriately, trial-based evaluations may provide data about uncertainties related to assessment of value for cost of new therapies that may be used by policy makers, drug manufacturers, health care providers and patients when therapy is first introduced in market